2001
DOI: 10.1006/bbrc.2001.5246
|View full text |Cite
|
Sign up to set email alerts
|

Role of PI3-Kinase in Isoproterenol and IGF-1 Induced ecNOS Activity

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
28
0

Year Published

2004
2004
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 37 publications
(29 citation statements)
references
References 18 publications
1
28
0
Order By: Relevance
“…5,21 Many stimuli (including insulin, vascular endothelial growth factor, ␤-agonists, and shear-stress signals) regulate NO production by activating eNOS via Ser-1177 phosphorylation through the PI3-kinase/Akt pathway. 10,11,22 When a PI3-K or Akt inhibitor was added in our study, there was no significant difference in the ACh-induced relaxation or in NO x Ϫ /cGMP production, whereas the clonidine-induced and insulin-induced responses were completely abolished by each inhibitor in control aortas. These observations suggest that clonidine-induced and insulin-induced vasorelaxations are regulated by the PI3-K/Akt signal pathway.…”
Section: Discussionmentioning
confidence: 50%
See 1 more Smart Citation
“…5,21 Many stimuli (including insulin, vascular endothelial growth factor, ␤-agonists, and shear-stress signals) regulate NO production by activating eNOS via Ser-1177 phosphorylation through the PI3-kinase/Akt pathway. 10,11,22 When a PI3-K or Akt inhibitor was added in our study, there was no significant difference in the ACh-induced relaxation or in NO x Ϫ /cGMP production, whereas the clonidine-induced and insulin-induced responses were completely abolished by each inhibitor in control aortas. These observations suggest that clonidine-induced and insulin-induced vasorelaxations are regulated by the PI3-K/Akt signal pathway.…”
Section: Discussionmentioning
confidence: 50%
“…Some studies have suggested a role for PI3-K/Akt in the induction of NO in the endothelium by insulin or ␤-agonists, because inhibition of such agonist-induced activations of PI3-K leads to impaired NO availability. 10,11 However, it is not known how (or whether) PI3-K/Akt/eNOS regulation is altered in the impaired endothelium-dependent relaxation seen in type 2 diabetic models.…”
mentioning
confidence: 99%
“…Many stimuli (including a 2 -agonists, insulin, vascular endothelial growth factor, b-agonists, estrogen, and shear-stress signals) regulate NO production by activating eNOS via Ser-1177 phosphorylation through the PI3-kinase/Akt pathway. [34][35][36][37] We previously found that in the mouse aorta, neither addition of LY294002 [an inhibitor of phosphatidylinositol 3 (PI3)-kinase] nor addtion of Akt inhibitor had any significant effect on the ACh-induced relaxation or on ACh-induced NO x /c-GMP production, whereas the clonidine-and insulin-induced relaxation responses were completely abolished by each of these inhibitors. 21,22) These observations suggest that in mouse aortas exposed to clonidine or insulin, both endothelium-dependent relaxation and NO production may be mediated or regulated by the PI3-kinase/Akt signal pathway.…”
Section: Discussionmentioning
confidence: 99%
“…In endothelial cells, the main signal-transduction pathway for agonist-stimulated eNOS activation depends on Ca 2ϩ /calmodulin/caveolin-1. At the cellular level, there is growing evidence that for some agonists, such as acetylcholine, histamine, and bradykinin, [37][38][39] a rise in intracellular Ca 2ϩ is necessary for NO production. In contrast, as already mentioned, for other stimuli (such as a 2 -agonists, insulin, and estrogen) a rise in Ca 2ϩ is not required, and NO production is activated by eNOS through the PI3-kinase/Akt patway.…”
Section: Discussionmentioning
confidence: 99%
“…More than half of the drugs currently in clinical use target GPCR by either mimicking endogenous GPCR ligands, blocking ligand access to the receptor or by modulating ligand production [14], which also represents the mechanism of action of sympatholytic and sympathomimetic drugs. Agonist-dependent desensitization of GPCR is caused by the phosphorylation of the specific receptor by the GRK family [15][16][17][18]. GRKs have a central catalytic domain flanked by amino-terminal and carboxyl-terminal domains which contain specific regulatory sites (Figure 1) [10].…”
Section: G Protein Related Kinases -General Overviewmentioning
confidence: 99%